ANI Non Current Liabilities Other from 2010 to 2025

ANIP Stock  USD 61.89  7.31  13.39%   
ANI Pharmaceuticals Non Current Liabilities Other yearly trend continues to be relatively stable with very little volatility. Non Current Liabilities Other is likely to drop to about 14.4 M. During the period from 2010 to 2025, ANI Pharmaceuticals Non Current Liabilities Other destribution of quarterly values had range of 36.4 M from its regression line and mean deviation of  11,057,460. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2010-12-31
Previous Quarter
19 M
Current Value
14.4 M
Quarterly Volatility
13 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 5.23. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of ANI Pharmaceuticals over the last few years. It is ANI Pharmaceuticals' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

ANI Non Current Liabilities Other Regression Statistics

Arithmetic Mean9,984,468
Geometric Mean0.00
Coefficient Of Variation130.38
Mean Deviation11,057,460
Median625,000
Standard Deviation13,017,299
Sample Variance169.5T
Range36.4M
R-Value0.71
Mean Square Error89.3T
R-Squared0.51
Significance0
Slope1,949,127
Total Sum of Squares2541.8T

ANI Non Current Liabilities Other History

202514.4 M
202419 M
202316.5 M
202236.4 M
202031 M
20196.5 M
2018496 K

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Other19 M14.4 M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.